```
=> d his

     (FILE 'HOME' ENTERED AT 12:44:14 ON 29 MAR 2010)

     FILE 'REGISTRY' ENTERED AT 12:44:25 ON 29 MAR 2010
L1             STRUCTURE UPLOADED
L2               4 S L1
L3            3639 S L1 SSS FUL
L4             STRUCTURE UPLOADED
L5            1690 S L4  SUB=L3 FUL
L6            1165 S L5 AND 5-6-7/SZ
L7             488 S L5 AND 5-6-6-7/SZ
L8             525 S L5 NOT L6
L9              37 S L8 NOT L7
L10           1202 S L5 NOT L7
L11           2437 S L3 NOT L10

     FILE 'CAPLUS' ENTERED AT 12:58:48 ON 29 MAR 2010
L12            469 S L11

     FILE 'REGISTRY' ENTERED AT 13:00:34 ON 29 MAR 2010
L13           1949 S L3 NOT L5

     FILE 'CAPLUS' ENTERED AT 13:02:12 ON 29 MAR 2010
L14            271 S L13

     FILE 'REGISTRY' ENTERED AT 13:02:47 ON 29 MAR 2010
L15            STRUCTURE UPLOADED
L16           1268 S L15  SUB=L3 FUL
L17             95 S L16 NOT L5
L18             78 S L17 AND CAPLUS/LC
L19             17 S L17 NOT L18

     FILE 'CAPLUS' ENTERED AT 13:08:52 ON 29 MAR 2010
L20             22 S L17
L21             18 S L20 NOT (2010/SO OR 2009/SO OR 2008/SO OR 2007/SO OR 2006/SO

=> d l1
L1 HAS NO ANSWERS
L1             STR
```




```
G1 C,N
G2 O,S,N
```

Structure attributes must be viewed using STN Express query preparation.

=> d l4
L4 HAS NO ANSWERS
L4 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> d l15
L15 HAS NO ANSWERS
L15 STR



G1 C,N

G2 O,S,N

G3 A,Cy,H

Structure attributes must be viewed using STN Express query preparation.

=> d ibib abs hitstr total l21

L21 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:1050008 CAPLUS
DOCUMENT NUMBER: 151:236777
TITLE: FXR agonists for treating vitamin D associated diseases
INVENTOR(S): Harnish, Douglas
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 53pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090215748	A1	20090827	US 2008-318039	20081219
PRIORITY APPLN. INFO.:			US 2007-8307P P	20071220

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Provided are certain methods of treating at least one condition that can be treated by elevating the vitamin D receptor (VDR) activity level in a patient with at least one farnesoid X receptor (FXR) agonist. Also provided are certain methods of modulating levels of Cytochrome P 450, family 27, subfamily B, polypeptide 1 (CYP27B1) and 1α,25-dihydroxyvitamin D3 in cells, certain methods of modulating VDR activity levels, certain methods of modulating levels of an extracellular matrix protein, renin angiotensin system (RAS) pathway, parathyroid hormone, serum creatinine, serum albumin, proteinuria, lipid metabolism, renal lipid deposition, mesangial expansion, glomerulosclerosis, kidney inflammation, blood pressure, bone resorption, and bone formation, certain methods of identifying FXR modulators, certain methods of diagnosing the risk that a patient will develop at least one condition that can be treated by elevating the VDR activity level, and certain methods of characterizing the levels of FXR activity in mammals.

IT 837429-85-3 837429-86-4 837429-88-6
837429-90-0, 6-(3,4-Difluoro-benzoyl)-4,4-dimethyl-5,6-dihydro-4H-thieno[2,3-d]azepine-8-carboxylic acid ethyl ester 837429-91-1
837429-92-2 837429-93-3 1088713-88-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(FXR agonists for treating vitamin D associated diseases)

RN 837429-85-3 CAPLUS
CN Imidazo[4,5-d]azepine-4-carboxylic acid, 6-(4-fluorobenzoyl)-3,6,7,8-tetrahydro-, ethyl ester (CA INDEX NAME)



RN 837429-86-4 CAPLUS

CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid, 6-(3,4-difluorobenzoyl)-5,6-dihydro-, ethyl ester (CA INDEX NAME)



RN 837429-88-6 CAPLUS
CN Azepino[4,5-b]indole-5-carboxylic acid, 3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-, ethyl ester (CA INDEX NAME)



RN 837429-90-0 CAPLUS
CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid, 6-(3,4-difluorobenzoyl)-5,6-dihydro-4,4-dimethyl-, ethyl ester (CA INDEX NAME)



RN 837429-91-1 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-diethyl ester (CA INDEX NAME)



RN 837429-92-2 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2-ethyl 8-(1-methylethyl) ester (CA INDEX NAME)



RN 837429-93-3 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-1,4,4-trimethyl-, 2-ethyl 8-(1-methylethyl) ester (CA INDEX NAME)



RN 1088713-88-5 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-dimethyl ester (CA INDEX NAME)


O
F
C— OMe
O
F
H
N
O
C— OMe
C
N
Me
Me

L21 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:769550 CAPLUS
DOCUMENT NUMBER: 151:94051
TITLE: Farnesoid X receptor (FXR) agonists for the treatment of nonalcoholic fatty liver and cholesterol gallstone diseases
INVENTOR(S): Zhang, Songwen; Harnish, Douglas; Evans, Mark J.; Wang, Juan
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 61pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090163474	A1	20090625	US 2008-253010	20081016
PRIORITY APPLN. INFO.:			US 2007-960925P P	20071019

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention provides methods for treating nonalcoholic fatty liver disease with farnesoid X receptor (FXR) agonists. The invention also provides methods for modulating levels of keratinocyte-derived chemokine (KC), alanine aminotransferase (ALT), aspartate aminotransferase (AST), cytokeratin 18 (CK-18), matrix metalloproteinase-9 (MMP-9), matrix metalloproteinase-14 (MMP-14), tissue inhibitor of metalloproteinase 1 (TIMP-1), and Cytochrome P 450 2E1 (CYP2E1); methods for identifying FXR modulators; and methods for treating patients with existing cholesterol gallstone disease.

IT 837429-85-3 837429-86-4 837429-89-7
837429-90-0 837429-91-1 837429-92-2
837429-93-3 1088713-88-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(FXR agonist for treatment of nonalcoholic fatty liver and cholesterol gallstone disease)

RN 837429-85-3 CAPLUS
CN Imidazo[4,5-d]azepine-4-carboxylic acid, 6-(4-fluorobenzoyl)-3,6,7,8-tetrahydro-, ethyl ester (CA INDEX NAME)



RN 837429-86-4 CAPLUS
CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid, 6-(3,4-difluorobenzoyl)-5,6-dihydro-, ethyl ester (CA INDEX NAME)



RN 837429-89-7 CAPLUS
CN Azepino[4,5-b]indole-5-carboxylic acid, 3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-1,1-dimethyl-, ethyl ester (CA INDEX NAME)



RN 837429-90-0 CAPLUS
CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid, 6-(3,4-difluorobenzoyl)-5,6-dihydro-4,4-dimethyl-, ethyl ester (CA INDEX NAME)



RN 837429-91-1 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-diethyl ester (CA INDEX NAME)



RN 837429-92-2 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2-ethyl 8-(1-methylethyl) ester (CA INDEX NAME)



RN 837429-93-3 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-1,4,4-trimethyl-, 2-ethyl 8-(1-methylethyl) ester (CA INDEX NAME)



RN 1088713-88-5 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-dimethyl ester (CA INDEX NAME)


F
F
O
C
N
O
C
OMe
H
N
O
C
OMe
Me
Me

L21 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:647976 CAPLUS
DOCUMENT NUMBER: 151:1373
TITLE: 1,4,5,6-Tetrahydropyrrolo[2,3-d]azepines AND -imidazo[4,5-d]azepines as modulators of nuclear receptor activity
INVENTOR(S): Mehlmann, John Francis; Lundquist, Joseph Theodore, IV; Mahaney, Paige Erin; Crawley, Matthew Lantz; Kim, Callain Younghee
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 26pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20090137554	A1	20090528	US 2008-255216		20081021
PRIORITY APPLN. INFO.:			US 2007-999990P	P	20071022

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 151:1373
GI



I

AB Disclosed are chemical entities including compds. of Formula (I and pharmaceutically acceptable salts thereof, wherein X is chosen from CN, CF3, CF2H, S(O)nR8, and S(O)2N(R9)R10; n is 1, 2 or 3; Y is chosen from CR11 and N; Z is chosen from O and NH; R1 is chosen from optionally substituted alkyl, cycloalkyl, etc.; R2 is H or optionally substituted alkyl; R3 is chosen from -C(O)R12 and -C(O)N(R9)R10; R4, R5, R6 and R7 are independently chosen from H and optionally substituted alkyl; R8 is chosen from optionally substituted alkyl or cycloalkyl; R9 and R10 is chosen from H or optionally substituted aryl or heteroaryl, etc.; R11 is H or lower alkyl; R12 is H, optionally substituted aryl or heteroaryl, etc.); compns. comprising one or more such chemical entities; and methods of using one or more such chemical entities for modulating the activity of certain nuclear receptors (e.g., farnesoid X) or for the treatment or prevention of one or more symptoms of disease or disorder related to the activity of those receptors.
IT 1158716-04-1P 1158716-05-2P 1158716-06-3P
1158716-07-4P 1158716-08-5P 1158716-09-6P

1158716-10-9P 1158716-11-0P 1158716-12-1P
1158716-13-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tetrahydropyrroloazepines and -imidazoazepines as modulators of farnesoid X receptors for disease treatment)

RN 1158716-04-1 CAPLUS
CN Pyrrolo[2,3-d]azepine-8-carboxylic acid, 2-cyano-6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 1-methylethyl ester (CA INDEX NAME)



RN 1158716-05-2 CAPLUS
CN Pyrrolo[2,3-d]azepine-8-carboxylic acid, 2-cyano-6-(cyclohexylcarbonyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 1-methylethyl ester (CA INDEX NAME)



RN 1158716-06-3 CAPLUS
CN Pyrrolo[2,3-d]azepine-8-carboxylic acid, 2-cyano-6-(3-fluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 1-methylethyl ester (CA INDEX NAME)



RN 1158716-07-4 CAPLUS
CN Pyrrolo[2,3-d]azepine-8-carboxylic acid, 2-cyano-6-(4-fluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 1-methylethyl ester (CA INDEX NAME)



RN 1158716-08-5 CAPLUS
CN Pyrrolo[2,3-d]azepine-8-carboxylic acid, 2-cyano-6-(4-cyanobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 1-methylethyl ester (CA INDEX NAME)



RN 1158716-09-6 CAPLUS
CN Pyrrolo[2,3-d]azepine-8-carboxylic acid, 6-(3-chlorobenzoyl)-2-cyano-1,4,5,6-tetrahydro-4,4-dimethyl-, 1-methylethyl ester (CA INDEX NAME)



RN 1158716-10-9 CAPLUS
CN Pyrrolo[2,3-d]azepine-8-carboxylic acid,
2-cyano-1,4,5,6-tetrahydro-4,4-dimethyl-6-(2-thienylcarbonyl)-,
1-methylethyl ester (CA INDEX NAME)



RN 1158716-11-0 CAPLUS
CN Pyrrolo[2,3-d]azepine-8-carboxylic acid,
2-cyano-1,4,5,6-tetrahydro-4,4-dimethyl-6-[3-(trifluoromethyl)benzoyl]-,
1-methylethyl ester (CA INDEX NAME)



RN 1158716-12-1 CAPLUS
CN Pyrrolo[2,3-d]azepine-8-carboxylic acid,
2-cyano-1,4,5,6-tetrahydro-4,4-dimethyl-6-[(tetrahydro-2H-pyran-4-yl)carbonyl]-, 1-methylethyl ester (CA INDEX NAME)



RN 1158716-13-2 CAPLUS
CN Spiro[4H-pyran-4,4'(1'H)-pyrrolo[2,3-d]azepine]-8'-carboxylic acid, 2'-cyano-6'-(3,4-difluorobenzoyl)-2,3,5,5',6,6'-hexahydro-, 1-methylethyl ester (CA INDEX NAME)



IT 1155659-03-2P 1158716-22-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(tetrahydropyrroloazepines and -imidazoazepines as modulators of farnesoid X receptors for disease treatment)

RN 1155659-03-2 CAPLUS
CN Pyrrolo[2,3-d]azepine-8-carboxylic acid, 2-cyano-1,4,5,6-tetrahydro-4,4-dimethyl-, 1-methylethyl ester (CA INDEX NAME)



RN 1158716-22-3 CAPLUS
CN Spiro[4H-pyran-4,4'(1'H)-pyrrolo[2,3-d]azepine]-8'-carboxylic acid,

2'-cyano-2,3,5,5',6,6'-hexahydro-, 1-methylethyl ester (CA INDEX NAME)



L21 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:615712 CAPLUS
DOCUMENT NUMBER: 150:555909
TITLE: 1,4,5,6,7,8-Hexahydro-pyrrolo[2,3-d]azepines and -imidazo[4,5-d]azepines as modulators of nuclear receptor activity
INVENTOR(S): Mehlmann, John Francis; Lundquist, Joseph Theodore, IV; Mahaney, Paige Erin; Crawley, Matthew Lantz; Kim, Callain Younghee
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 25pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090131409	A1	20090521	US 2008-255232	20081021
PRIORITY APPLN. INFO.:			US 2007-11P P	20071022

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 150:555909
GI



I

AB Disclosed are chemical entities including compds. of Formula (I and pharmaceutically acceptable salts thereof, wherein X is chosen from CN, CF3, CF2H, S(O)nR8, and S(O)2N(R9)R10; n is 1, 2 or 3; Y is chosen from CR11 and N; Z is chosen from O and NH; R1 is chosen from optionally substituted alkyl, cycloalkyl, etc.; R2 is H or optionally substituted alkyl; R3 is chosen from -C(O)R12 and -C(O)N(R9)R10; R4, R5, R6 and R7 are independently chosen from H and optionally substituted alkyl; R8 is chosen from optionally substituted alkyl or cycloalkyl; R9 and R10 is chosen from H or optionally substituted aryl or heteroaryl, etc.; R11 is H or lower alkyl; R12 is H, optionally substituted aryl or heteroaryl, etc.); compns. comprising one or more such chemical entities; and methods of using one or more such chemical entities for modulating the activity of certain nuclear receptors (e.g., farnesoid X) or for the treatment or prevention of one or more symptoms of disease or disorder related to the activity of those receptors.
IT 1155659-03-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(hexahydro-pyrroloazepines and -imidazoazepines as modulators of farnesoid X receptor activity for treatment of disease)

RN 1155659-03-2 CAPLUS

CN Pyrrolo[2,3-d]azepine-8-carboxylic acid, 2-cyano-1,4,5,6-tetrahydro-4,4-dimethyl-, 1-methylethyl ester (CA INDEX NAME)



L21 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1457368 CAPLUS
DOCUMENT NUMBER: 150:16134
TITLE: Farnesoid X receptor (FXR) agonists for reducing lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1) expression, and therapeutic use
INVENTOR(S): Harnish, Douglas; Zhang, Songwen
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 26pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20080300235	A1	20081204	US 2008-130322		20080530
PRIORITY APPLN. INFO.:			US 2007-924822P	P	20070601

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The invention provides methods for treating at least one disease state characterized by elevated expression of the lectin-like oxidized low-d. lipoprotein receptor 1 (LOX-1) in a patient with farnesoid X receptor (FXR) agonists. Also provided are methods for reducing expression of LOX-1 in a cell with FXR agonists.
IT 837429-85-3, 6-(4-Fluorobenzoyl)-3,6,7,8-tetrahydroimidazo(4,5-d)azepine-4-carboxylic acid ethyl ester 837429-86-4, 6-(3,4-Difluorobenzoyl)-5,6-dihydro-4H-thieno(2,3-d)azepine-8-carboxylic acid ethyl ester 837429-88-6, 3-(4-Fluorobenzoyl)1,2,3,6,7,8,9,10-octahydroazepino[4,5-b]indole-5-carboxylic acid ethyl ester 837429-89-7, 3-(4-Fluorobenzoyl)-1,1-dimethyl-1,2,3,6,7,8,9,10-octahydroazepino[4,5-b]indole-5-carboxylic acid ethyl ester 837429-90-0 837429-91-1, 6-(3,4-Difluorobenzoyl)-4,4-dimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid diethyl ester 837429-92-2 837429-93-3 1088713-88-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(FXR agonists for reducing LOX-1 expression, and therapeutic use)
RN 837429-85-3 CAPLUS
CN Imidazo[4,5-d]azepine-4-carboxylic acid, 6-(4-fluorobenzoyl)-3,6,7,8-tetrahydro-, ethyl ester (CA INDEX NAME)



RN 837429-86-4 CAPLUS
CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid, 6-(3,4-difluorobenzoyl)-5,6-dihydro-, ethyl ester (CA INDEX NAME)



RN 837429-88-6 CAPLUS
CN Azepino[4,5-b]indole-5-carboxylic acid, 3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-, ethyl ester (CA INDEX NAME)



RN 837429-89-7 CAPLUS
CN Azepino[4,5-b]indole-5-carboxylic acid, 3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-1,1-dimethyl-, ethyl ester (CA INDEX NAME)



RN 837429-90-0 CAPLUS
CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid, 6-(3,4-difluorobenzoyl)-5,6-dihydro-4,4-dimethyl-, ethyl ester (CA INDEX NAME)



RN 837429-91-1 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-diethyl ester (CA INDEX NAME)



RN 837429-92-2 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2-ethyl 8-(1-methylethyl) ester (CA INDEX NAME)



RN 837429-93-3 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-1,4,4-trimethyl-, 2-ethyl 8-(1-methylethyl) ester (CA INDEX NAME)



RN 1088713-88-5 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-dimethyl ester (CA INDEX NAME)



L21 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1455334 CAPLUS
DOCUMENT NUMBER: 150:16058
TITLE: FXR agonists for the treatment of malignancies
INVENTOR(S): Hartman, Helen B.; Evans, Mark J.
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 25pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080299118	A1	20081204	US 2008-130221	20080530
PRIORITY APPLN. INFO.:			US 2007-924823P P	20070601

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Provided are certain methods of treating malignancies with farnesoid X receptor agonists. Also provided are certain methods of inducing RECK gene expression with farnesoid X receptor agonists and methods of reducing at least one feature of a cell with farnesoid X receptor agonists.

IT 837429-85-3, 6-(4-Fluorobenzoyl)-3,6,7,8-tetrahydroimidazo[4,5-D]azepine-4-carboxylic acid ethyl ester 837429-86-4, 6-(3,4-Difluorobenzoyl)-5,6-dihydro-4H-thieno[2,3-D]azepine-8-carboxylic acid ethyl ester 837429-88-6, 3-(4-Fluorobenzoyl)1,2,3,6,7,8,9,10-octahydroazepino[4,5-b]indole-5-carboxylic acid ethyl ester 837429-89-7, 3-(4-Fluorobenzoyl)-1,1-dimethyl-1,2,3,6,7,8,9,10-octahydroazepino[4,5-b]indole-5-carboxylic acid ethyl ester 837429-90-0, 6-(3,4-Difluorobenzoyl)-4,4-dimethyl-5,6-dihydro-4H-thieno[2,3-d]azepine-8-carboxylic acid ethyl ester 837429-91-1, 6-(3,4-Difluorobenzoyl)-4,4-dimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid diethyl ester 837429-92-2 837429-93-3 1088713-88-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(farnesoid X receptor agonists for treatment of malignancies by inducing RECK gene expression)

RN 837429-85-3 CAPLUS
CN Imidazo[4,5-d]azepine-4-carboxylic acid, 6-(4-fluorobenzoyl)-3,6,7,8-tetrahydro-, ethyl ester (CA INDEX NAME)



RN 837429-86-4 CAPLUS
CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid, 6-(3,4-difluorobenzoyl)-5,6-dihydro-, ethyl ester (CA INDEX NAME)



RN 837429-88-6 CAPLUS
CN Azepino[4,5-b]indole-5-carboxylic acid, 3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-, ethyl ester (CA INDEX NAME)



RN 837429-89-7 CAPLUS
CN Azepino[4,5-b]indole-5-carboxylic acid, 3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-1,1-dimethyl-, ethyl ester (CA INDEX NAME)



RN 837429-90-0 CAPLUS
CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid, 6-(3,4-difluorobenzoyl)-5,6-dihydro-4,4-dimethyl-, ethyl ester (CA INDEX NAME)



RN 837429-91-1 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-diethyl ester (CA INDEX NAME)



RN 837429-92-2 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2-ethyl 8-(1-methylethyl) ester (CA INDEX NAME)



RN 837429-93-3 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-1,4,4-trimethyl-, 2-ethyl 8-(1-methylethyl) ester (CA INDEX NAME)



RN 1088713-88-5 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-dimethyl ester (CA INDEX NAME)



L21 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:1210238 CAPLUS
DOCUMENT NUMBER: 147:489055
TITLE: Electrode material, and secondary battery and capacitor using the electrode
INVENTOR(S): Sarukawa, Tomoo; Taniguchi, Masahiko; Koyama, Noboru
PATENT ASSIGNEE(S): Fuji Heavy Industries Ltd., Japan; Tokyo University of Agriculture & Technology
SOURCE: Jpn. Kokai Tokkyo Koho, 11pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007280747	A	20071025	JP 2006-104899	20060406

PRIORITY APPLN. INFO.: JP 2006-104899 20060406
GI



I

AB The electrode material comprises a S-containing aromatic polymer represented by:
I (m = 0 or 1; and n = integer 2-200). The battery has a cathode using the above electrode material, an anode using a Li-intercalating material, and a nonaq. electrolyte solution The capacitor has a cathode using the above electrode material, a nonaq. electrolyte solution, and an anode using a material capable of doping/dedoping cations in the electrolyte solution
IT 954111-92-3
RL: TEM (Technical or engineered material use); USES (Uses)
(cathodes having S-containing aromatic polymers for secondary batteries)
RN 954111-92-3 CAPLUS
CN Poly(naphtho[1,8-cd:4,5-c'd']bis[1,2]dithiole-3,4:7,8-tetrayl-7,8-diimino) (CA INDEX NAME)


S
S
S
S
NH
NH
n

L21 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:99333 CAPLUS
DOCUMENT NUMBER: 142:198048
TITLE: Azepine derivatives as pharmaceutical agents, specifically as farnesoid X receptor ligands, and their preparation, pharmaceutical compositions, and use in the treatment of lipid disorders, atherosclerosis, and diabetes
INVENTOR(S): Martin, Richard; Wang, Tie-Lin; Flatt, Brenton T.; Gu, Xiao-Hui
PATENT ASSIGNEE(S): X-Ceptor Therapeutics Inc., USA
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009387	A2	20050203	WO 2004-US23745	20040723
WO 2005009387	A3	20060302		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004259009	A1	20050203	AU 2004-259009	20040723
CA 2532798	A1	20050203	CA 2004-2532798	20040723
EP 1648408	A1	20060426	EP 2004-779004	20040723
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004012262	A	20060919	BR 2004-12262	20040723
CN 1852748	A	20061025	CN 2004-80027076	20040723
JP 2006528637	T	20061221	JP 2006-521272	20040723
KR 2006052867	A	20060519	KR 2006-701566	20060123
MX 2006000875	A	20060907	MX 2006-875	20060123
NO 2006000871	A	20060424	NO 2006-871	20060222
US 20070015746	A1	20070118	US 2006-565702	20060913
PRIORITY APPLN. INFO.:			US 2003-489854P P	20030723
			WO 2004-US23745 W	20040723

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 142:198048; MARPAT 142:198048
GI



I



II

AB Compds., compns., and methods are provided for modulating the activity of farnesoid X receptors, and for the treatment, prevention, or amelioration of one or more symptoms of diseases or disorders related to the activity of the receptors. In particular, compds. I are disclosed [wherein: X = O, S(O)0-2, NH or its alkyl, acylated, oxyacylated, or sulfonylated derivs.; Y = (un)substituted CH or N; Z = (un)substituted CH or N; or YZ bond is fused to a carbo- or heterocyclic ring, but not benzo or naphtho; R1, R2, R4-R7 = H, halo, (un)substituted alk(en/yn)yl, (hetero)aryl, numerous functional groups; R3 = H, (un)substituted alk(en/yn)yl, (hetero)aryl, numerous functional groups; R4R5 and/or R6R7 may form oxo, thioxo, (un)substituted imino or oxime or hydrazone, or an exocyclic double bond; or R4R5, R4R6, R4R7, R5R6, R5R7, and/or R6R7 may form ring(s); including isomer(s), solvates, polymorphs, prodrugs, and pharmaceutically acceptable salts]. Fifteen synthetic examples and several biol. examples are given. For instance, thiophene-3-acetonitrile was converted to invention compound II in four steps: (1) di-α-methylation using NaH and MeI in DMF; (2) reduction of the nitrile to a primary amine using LiAlH4; (3) cyclocondensation of the amine with Et bromopyruvate to form the azepine ring; and (4) N-acylation using 3,4-difluorobenzoyl chloride. II exhibited agonist activity at 100 nM or less, with > 100% efficacy (vs. CDCA), as measured in a co-transfection assay using full length human farnesoid X receptor.

IT 837429-84-2P, 3,6,7,8-Tetrahydroimidazo[4,5-d]azepine-4-carboxylic acid ethyl ester
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of azepine derivs. as farnesoid X receptor ligands for treatment of lipid disorders, atherosclerosis, and diabetes)

RN 837429-84-2 CAPLUS

CN Imidazo[4,5-d]azepine-4-carboxylic acid, 3,6,7,8-tetrahydro-, ethyl ester (CA INDEX NAME)



IT 837429-85-3P, 6-(4-Fluorobenzoyl)-3,6,7,8-tetrahydroimidazo[4,5-d]azepine-4-carboxylic acid ethyl ester 837429-86-4P, 6-(3,4-Difluorobenzoyl)-5,6-dihydro-4H-thieno[2,3-d]azepine-8-carboxylic acid ethyl ester 837429-88-6P, 3-(4-Fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydroazepino[4,5-b]indole-5-carboxylic acid ethyl ester 837429-89-7P, 3-(4-Fluorobenzoyl)-1,1-dimethyl-1,2,3,6,7,8,9,10-octahydroazepino[4,5-b]indole-5-carboxylic acid ethyl ester 837429-90-0P, 6-(3,4-Difluorobenzoyl)-4,4-dimethyl-5,6-dihydro-4H-thieno[2,3-d]azepine-8-carboxylic acid ethyl ester 837429-91-1P, 6-(3,4-Difluorobenzoyl)-4,4-dimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid diethyl ester 837429-92-2P, 6-(3,4-Difluorobenzoyl)-4,4-dimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid 2-ethyl ester 8-isopropyl ester 837429-93-3P, 6-(3,4-Difluorobenzoyl)-1,4,4-trimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid 2-ethyl ester 8-isopropyl ester
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of azepine derivs. as farnesoid X receptor ligands for treatment of lipid disorders, atherosclerosis, and diabetes)

RN 837429-85-3 CAPLUS
CN Imidazo[4,5-d]azepine-4-carboxylic acid, 6-(4-fluorobenzoyl)-3,6,7,8-tetrahydro-, ethyl ester (CA INDEX NAME)



RN 837429-86-4 CAPLUS
CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid, 6-(3,4-difluorobenzoyl)-5,6-dihydro-, ethyl ester (CA INDEX NAME)



RN 837429-88-6 CAPLUS
CN Azepino[4,5-b]indole-5-carboxylic acid, 3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-, ethyl ester (CA INDEX NAME)



RN 837429-89-7 CAPLUS
CN Azepino[4,5-b]indole-5-carboxylic acid, 3-(4-fluorobenzoyl)-1,2,3,6,7,8,9,10-octahydro-1,1-dimethyl-, ethyl ester (CA INDEX NAME)



RN 837429-90-0 CAPLUS
CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid, 6-(3,4-difluorobenzoyl)-5,6-dihydro-4,4-dimethyl-, ethyl ester (CA INDEX NAME)



RN 837429-91-1 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-diethyl ester (CA INDEX NAME)



RN 837429-92-2 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-4,4-dimethyl-, 2-ethyl 8-(1-methylethyl) ester (CA INDEX NAME)



RN 837429-93-3 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 6-(3,4-difluorobenzoyl)-1,4,5,6-tetrahydro-1,4,4-trimethyl-, 2-ethyl 8-(1-methylethyl) ester (CA INDEX NAME)



IT 837429-95-5P, 5,6-Dihydro-4H-thieno[2,3-d]azepine-8-carboxylic acid ethyl ester 837429-96-6P, 4,4-Dimethyl-5,6-dihydro-4H-thieno[2,3-d]azepine-8-carboxylic acid ethyl ester 837430-02-1P, 4,4-Dimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid diethyl ester 837430-03-2P, 4,4-Dimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid 2-ethyl ester 8-isopropyl ester 837430-05-4P, 1,4,4-Trimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-2,8-dicarboxylic acid 2-ethyl ester 8-isopropyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of azepine derivs. as farnesoid X receptor ligands for treatment of lipid disorders, atherosclerosis, and diabetes)

RN 837429-95-5 CAPLUS
CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid, 5,6-dihydro-, ethyl ester (CA INDEX NAME)



RN 837429-96-6 CAPLUS
CN 4H-Thieno[2,3-d]azepine-8-carboxylic acid, 5,6-dihydro-4,4-dimethyl-, ethyl ester (CA INDEX NAME)



RN 837430-02-1 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 1,4,5,6-tetrahydro-4,4-dimethyl-, 2,8-diethyl ester (CA INDEX NAME)



RN 837430-03-2 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 1,4,5,6-tetrahydro-4,4-dimethyl-, 2-ethyl 8-(1-methylethyl) ester (CA INDEX NAME)



RN 837430-05-4 CAPLUS
CN Pyrrolo[2,3-d]azepine-2,8-dicarboxylic acid, 1,4,5,6-tetrahydro-1,4,4-trimethyl-, 2-ethyl 8-(1-methylethyl) ester (CA INDEX NAME)



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	1	THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2000:841864 CAPLUS
DOCUMENT NUMBER: 134:17397
TITLE: Preparation of 3-aminomethylene-2-indolinonecarboxylates as cell proliferation inhibitors
INVENTOR(S): Heckel, Armin; Walter, Rainer; Roth, Gerald; Vanm Meel, Jacobus; Redemann, Norbert; Tontsch-Grunt, Ulrike; Spevak, Walter
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: Ger. Offen., 28 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19924401	A1	20001130	DE 1999-19924401	19990527
WO 2000073297	A1	20001207	WO 2000-EP4685	20000523

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: DE 1999-19924401 A 19990527
OTHER SOURCE(S): CASREACT 134:17397; MARPAT 134:17397
GI



I

AB Title compds. [I; R1 = H, alkanoyl, alkoxycarbonyl; R2 = (un)substituted (di)alkylaminocarbonyl; X1 = CR3NR4R5; R3 = H, alkyl, (un)substituted Ph, etc.; R4 = alkyl, (un)substituted Ph, etc.; R5 = H or (un)substituted alkyl; X2 = O or S], inhibitors of cyclin-dependant kinases, were prepared Thus, Me 1-acetyl-2-indolinone-5-carboxylate was condensed with BuC(OEt)3 to give I (R2 = 5-COR, X2 = O)(II; R = OMe, R1 = Ac, X1 = CBuOEt). Similarly prepared II (X1 = CPhOEt) was aminated bu 4-(H2N)C6H4CH2NMeCH2Ph and the saponified product amidated by PhCH2NHMe to give II [R = PhCH2NMe, R1 = H, X1 = CPhNHC6H4(CH2NMeCH2Ph)-4]. Data for biol. activity of I were given.
IT 1175365-44-2 1175365-50-0
RL: PRPH (Prophetic)
(Preparation of 3-aminomethylene-2-indolinonecarboxylates as cell

proliferation inhibitors)
RN 1175365-44-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1175365-50-0 CAPLUS
CN 7H-Pyrazino[2,3-d]azepin-7-amine, 1,2,3,4,8,9-hexahydro-2-[(4-nitrophenyl)methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L21 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2000:441796 CAPLUS
DOCUMENT NUMBER: 133:74016
TITLE: preparation of spirotricyclic compounds as H1 receptor antagonists
INVENTOR(S): Janssens, Frans Eduard; Leenaerts, Joseph Elisabeth
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037470	A1	20000629	WO 1999-EP10176	19991215
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2355939	A1	20000629	CA 1999-2355939	19991215
BR 9916371	A	20010918	BR 1999-16371	19991215
EP 1144411	A1	20011017	EP 1999-964625	19991215
EP 1144411	B1	20050427		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101711	T2	20011221	TR 2001-1711	19991215
HU 2001004779	A2	20020429	HU 2001-4779	19991215
HU 2001004779	A3	20031229		
EE 200100328	A	20020815	EE 2001-328	19991215
EE 4917	B1	20071015		
JP 2002533344	T	20021008	JP 2000-589540	19991215
AU 764820	B2	20030828	AU 2000-30412	19991215
NZ 512870	A	20031128	NZ 1999-512870	19991215
AT 294178	T	20050515	AT 1999-964625	19991215
PT 1144411	E	20050930	PT 1999-964625	19991215
ES 2242443	T3	20051101	ES 1999-964625	19991215
CN 1258533	C	20060607	CN 1999-814705	19991215
PL 196262	B1	20071231	PL 1999-348295	19991215
SK 286158	B6	20080407	SK 2001-814	19991215
TW 250981	B	20060311	TW 1999-88122194	19991217
IN 2001MN00441	A	20050304	IN 2001-MN441	20010423
BG 105546	A	20011231	BG 2001-105546	20010529
BG 65133	B1	20070330		
NO 2001002710	A	20010601	NO 2001-2710	20010601
NO 318891	B1	20050518		
HR 2001000453	A2	20020630	HR 2001-453	20010615
MX 2001006244	A	20010910	MX 2001-6244	20010618
ZA 2001004977	A	20020618	ZA 2001-4977	20010618
US 7148214	B1	20061212	US 2001-868535	20010726
HK 1043128	A1	20070119	HK 2002-104999	20020703
US 20050026901	A1	20050203	US 2004-898844	20040726

US 7087595 B2 20060808
PRIORITY APPLN. INFO.: EP 1998-204347 A 19981219
WO 1999-EP10176 W 19991215
US 2001-868535 A1 20010726
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 133:74016
GI



I

AB Title compds. [I; R = Z2Z3R5, Z2NHCOR5, Z2R5; R1 = H, halo, alkyl, acyl, etc.; R2 = H, halo, alkyl, aryl, etc.; R3R4 = YCH:CH, CH:CHY, CH:CHCH:CH; R5 = (un)substituted heteroaryl, -tetrahydrofuranyl, etc.; Y = O, S, (alkyl)imino, alkanoylimino; Z = alkylene, CH:CH, CH2CH(OH), CH2O, etc.; Z1 = CH2 or CH2CH2; Z3 = O, S, NH] were prepared Thus, 1-phenylmethyl-1H-imidazole was condensed with 1-phenylmethyl-4-piperidone and the product cyclized to give, after hydrogenation, I (R1 = R2 = H, R3R4 = CH:CHCH:CH, Z = CH2, Z1 = CH2CH2) (II; R = H) which was N-alkylated by 1-(2-bromoethyl)-4-ethyl-1,4-dihydro-5H-tetrazol-5-one to give II [R = 2-(4-ethyl-5-oxo-1,4-dihydro-1H-tetrazol-1-yl)ethyl]. Data for biol. activity of I were given.

IT 279253-82-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of spirotricyclic compds. as H1 receptor antagonists)

RN 279253-82-6 CAPLUS

CN Spiro[cyclohexane-1,10'-[10H]imidazo[1,2-a]thieno[3,2-d]azepine], (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 279253-81-5
CMF C15 H16 N2 S

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



OS.CITING REF COUNT:	5	THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
REFERENCE COUNT:	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1994:605360 CAPLUS
DOCUMENT NUMBER: 121:205360
ORIGINAL REFERENCE NO.: 121:37397a,37400a
TITLE: Preparation of antiallergic triazolo(pyrrolo, thieno or furano)azepine derivatives
INVENTOR(S): Janssens, Frans Eduard; Lacrampe, Jean Fernand Armand; Pilatte, Isabelle Noelle Consta
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9413681	A1	19940623	WO 1993-EP3322	19931125
W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2150804	A1	19940623	CA 1993-2150804	19931125
CA 2150804	C	20061010		
AU 9456280	A	19940704	AU 1994-56280	19931125
AU 676703	B2	19970320		
EP 675889	A1	19951011	EP 1994-901888	19931125
EP 675889	B1	20000705		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
HU 71808	A2	19960228	HU 1995-1619	19931125
HU 223465	B1	20040728		
JP 08503954	T	19960430	JP 1994-513722	19931125
JP 3503065	B2	20040302		
RU 2127737	C1	19990320	RU 1995-115515	19931125
PL 176528	B1	19990630	PL 1993-309255	19931125
AT 194350	T	20000715	AT 1994-901888	19931125
ES 2149861	T3	20001116	ES 1994-901888	19931125
PT 675889	E	20001229	PT 1994-901888	19931125
US 5595988	A	19970121	US 1995-433387	19950508
FI 9502724	A	19950602	FI 1995-2724	19950602
NO 9502200	A	19950803	NO 1995-2200	19950602
NO 311619	B1	20011217		
GR 3034495	T3	20001229	GR 2000-402184	20000928

PRIORITY APPLN. INFO.:	EP 1992-203777	A	19921204
	EP 1994-901888	A	19931125
	WO 1993-EP3322	W	19931125

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 121:205360
GI



I



II

AB Title compds. I (E-G = XCR1CH, CH:CR2X wherein X = O, S or R3N wherein R3 =H, C1-6 alkyl, C1-4 alkylcarbonyl, R1, R2 = H, C1-4 alkyl, halo, (substituted)ethenyl, etc.; BD = CR4:N, N:CR5 wherein R4 H, C1-4 alkyl, (substituted)ethenyl, HO-C1-4 alkyl, HCO, HO2C, R5 = H, Ph, pyridinyl, etc.; L = H, (substituted)C1-6 alkyl, (aryl)C3-6 alkenyl, Alk-Y-Het, Alk-NHCO-Het, Alk-Het wherein Alk = C1-4 alkanediyl,, Y = O, S, NH, Het = (substituted)heterocyclyl) or a salt or stereomer thereof, are prepared (1-Methyl-4-piperidinyl)[1-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1H-1,2,4-triazol-5-yl]methanone (preparation given) was added to MeSO3H at 0° followed by NaOH to give after workup II. Pharmaceutical formulations comprising I are given.

IT 158144-23-1P 158144-25-3P 158144-26-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of antiallergy agents)

RN 158144-23-1 CAPLUS
CN 10H-Thieno[3,2-d]-1,2,4-triazolo[4,3-a]azepine (CA INDEX NAME)



RN 158144-25-3 CAPLUS
CN 10H-Thieno[3,2-d][1,2,4]triazolo[1,5-a]azepin-10-one (CA INDEX NAME)



RN 158144-26-4 CAPLUS
CN 10H-Thieno[3,2-d][1,2,4]triazolo[1,5-a]azepin-10-ol, 10-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



IT 158143-86-3P 158143-89-6P 158144-02-6P
158144-10-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiallergy agent)
RN 158143-86-3 CAPLUS
CN 10H-Thieno[3,2-d]-1,2,4-triazolo[4,3-a]azepine,
10-(1-methyl-4-piperidinylidene)- (CA INDEX NAME)



RN 158143-89-6 CAPLUS
CN Pyrrolo[3,2-d][1,2,4]triazolo[1,5-a]azepine,
7,10-dihydro-10-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]-7-methyl-
(CA INDEX NAME)



RN 158144-02-6 CAPLUS
CN 10H-Furo[3,2-d][1,2,4]triazolo[1,5-a]azepine, 8-methyl-10-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 158144-10-6 CAPLUS
CN 1-Piperidinepropanoic acid, 4-(10H-thieno[3,2-d]-1,2,4-triazolo[4,3-a]azepin-10-ylidene)-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT:	5	THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1993:213072 CAPLUS
DOCUMENT NUMBER: 118:213072
ORIGINAL REFERENCE NO.: 118:36731a,36734a
TITLE: Preparation of imidazo[1,2-a](pyrrolo, thieno or furano)[3,2-d]azepines as allergy inhibitors
INVENTOR(S): Janssens, Frans Eduard; Diels, Gaston Stanislas Marcella; Leenaerts, Joseph Elisabeth; Cooymans, Ludwig Paul
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: Eur. Pat. Appl., 60 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 518434	A1	19921216	EP 1992-201665	19920609
R: PT				
IL 101851	A	19960514	IL 1992-101851	19920513
CN 1068116	A	19930120	CN 1992-104830	19920516
CN 1033587	C	19961218		
CA 2102889	A1	19921214	CA 1992-2102889	19920609
CA 2102889	C	20021126		
WO 9222553	A1	19921223	WO 1992-EP1331	19920609
W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MW, NO, PL, RO, RU, SD, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
AU 9219011	A	19930112	AU 1992-19011	19920609
AU 652841	B2	19940908		
EP 588859	A1	19940330	EP 1992-911643	19920609
EP 588859	B1	20030813		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
JP 06507890	T	19940908	JP 1992-510734	19920609
JP 3182421	B2	20010703		
HU 70428	A2	19951030	HU 1993-3554	19920609
HU 221013	B1	20020729		
PL 170376	B1	19961231	PL 1992-301819	19920609
AT 247118	T	20030815	AT 1992-911643	19920609
ES 2204892	T3	20040501	ES 1992-911643	19920609
ZA 9204327	A	19931213	ZA 1992-4327	19920612
US 5461050	A	19951024	US 1993-150121	19931129
NO 9304493	A	19940104	NO 1993-4493	19931209
NO 300689	B1	19970707		
FI 104077	B1	19991115	FI 1993-5557	19931210

PRIORITY APPLN. INFO.: US 1991-714487 A 19910613
WO 1992-EP1331 A 19920609
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 118:213072
GI For diagram(s), see printed CA Issue.
AB Title compds. [I; R1 = H, alkyl, halo, ethenyl substituted with CO2H or alkoxycarbonyl, hydroxylalkyl, CHO, HO2C, hydroxycarbonylalkyl; R2 = H, alkyl, ethenyl or alkyl substituted with CO2H or alkoxy carbonyl, hydroxyalkyl, CHO, CO2H; R3 = H, alkyl, hydroxyalkyl, Ph, halo; L = H,

(substituted) alkyl, alkenyl, ZYQ1, ZNHCOQ2, ZQ3; Y = O, S, NH; Z = C1-4 alkylene; Q1, Q2 = (substituted) furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrrolyl, pyrazolyl, thiadiazolyl, oxodiazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazo[4,5-c]pyridin-2-yl; Q3 = Q1, (substituted) 4,5-dihydro-5-oxo-1H-tetrazolyl, 2-oxo-3-oxazolidinyl, 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl, etc.; X = O, S, NR5; R5 = H, alkyl, alkoxycarrbonyl; dotted lines = optional double bonds] were prepared as broad spectrum antiallergics with excellent oral availability, lack of sedating properties, fast onset of action, and favorable duration of action (no data). Thus, [2-(1-methyl-1H-pyrrol-2-yl)ethyl] methanesulfonate was refluxed 3 daysa with imidazole and K2CO3 in THF to give 61.7% 1-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1H-imidazole. The latter and then Et6 1-methyl-4-piperidinecarboxylate were added to a -70° mixture of (MyCH)2NH and BuLi in THF. The mixture was stirred 1 h at -70° and 2 h at room temperature ti give 60% (1-methyl-4-piperidinyl)[1-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1H-imidazol-2-yl]methanone. This was stirred with MeSO3H at 80° to give 10.8% title compound II. Pharmaceutical I formulations are given.

IT 146800-71-7P 146800-72-8P 147184-18-7P
147184-19-8P 147184-20-1P 147184-22-3P
147184-24-5P 147184-27-8P 147210-29-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as allergy inhibitor)

RN 146800-71-7 CAPLUS
CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepine, 10-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 146800-72-8 CAPLUS
CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepine, 10-(4-piperidinylidene)- (CA INDEX NAME)



RN 147184-18-7 CAPLUS
CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepine, 10-(1-methyl-4-piperidinylidene)-
(CA INDEX NAME)



RN 147184-19-8 CAPLUS
CN Imidazo[1,2-a]pyrrolo[3,2-d]azepine,
7,10-dihydro-7-methyl-10-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 147184-20-1 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-(10H-imidazo[1,2-a]thieno[3,2-d]azepin-10-
ylidene)-, ethyl ester (CA INDEX NAME)



RN 147184-22-3 CAPLUS
CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepine, 10-(4-piperidinylidene)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 147184-24-5 CAPLUS
CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepine, 10-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinylidene]-, ethanedioate (2:5) (CA INDEX NAME)

CM 1

CRN 147184-23-4
CMF C24 H25 N3 O S



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 147184-27-8 CAPLUS
CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepine, 10-(1-methyl-4-piperidinyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 147210-29-5 CAPLUS
CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[4-(10H-imidazo[1,2-a]thieno[3,2-d]azepin-10-ylidene)-1-piperidinyl]ethyl]-7-methyl-, ethanedioate (1:2) (CA INDEX NAME)

CM 1

CRN 147210-28-4
CMF C24 H23 N5 O S2



CM 2

CRN 144-62-7
CMF C2 H2 O4



IT 146800-88-6P, 4H-Thieno[2,3-d]azepin-5-amine 146800-89-7P 146800-90-0P, 10H-Imidazo[1,2-a]thieno[3,2-d]azepine 146800-91-1P 146800-92-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediates for imidazolazoloazepine inhibitor)
RN 146800-88-6 CAPLUS
CN 4H-Thieno[2,3-d]azepin-5-amine (CA INDEX NAME)



RN 146800-89-7 CAPLUS
CN 4H-Thieno[2,3-d]azepin-5-amine, N-(2,2-dimethoxyethyl)- (CA INDEX NAME)



RN 146800-90-0 CAPLUS
CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepine (CA INDEX NAME)



RN 146800-91-1 CAPLUS
CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepin-10-one (CA INDEX NAME)



RN 146800-92-2 CAPLUS
CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepin-10-ol, 10-(1-methyl-4-piperidinyl)-
(CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

L21 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1988:3637 CAPLUS
DOCUMENT NUMBER: 108:3637
ORIGINAL REFERENCE NO.: 108:707a,710a
TITLE: Marine alkaloids. 13. Chartellamide A and B, halogenated β-lactam indole-imidazole alkaloids from the marine bryozoan Chartella papyracea
AUTHOR(S): Anthoni, Uffe; Bock, Klaus; Chevolot, Lionel; Larsen, Charles; Nielsen, Per H.; Christophersen, Carsten
CORPORATE SOURCE: H. C. Oersted Inst., Univ. Copenhagen, Copenhagen, DK-2100, Den.
SOURCE: Journal of Organic Chemistry (1987), 52(25), 5638-9
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I, R=H
II, R=Br

AB Chartellamide A (I) and B (II) were isolated from the EtOAc extract of the marine bryozoan C. papyracea and their structures were determined by spectroscopic analyses including mass, IR, UV, and 1H-NMR spectroscopy.
IT 111268-63-4 111268-64-5
RL: BIOL (Biological study)
(of marine bryozoan, isolation and mol. structure of)
RN 111268-63-4 CAPLUS
CN 3,6-Methano-3H,4H-azeto[1',2':1,2]imidazo[4',5':4,5]azepino[3,2-b]pyrrolo[1,2-a]indole-13,17(12H)-dione, 5,9,11,16-tetrabromo-5,6-dihydro-6-methyl-, (3S,3bS,5R,6R,11bS)- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 111268-64-5 CAPLUS
CN 3,6-Methano-3H,4H-azeto[1',2':1,2]imidazo[4',5':4,5]azepino[3,2-b]pyrrolo[1,2-a]indole-13,17(12H)-dione, 2,5,9,11,16-pentabromo-5,6-dihydro-6-methyl-, (3R,3bS,5R,6R,11bS)- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)

L21 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1979:204018 CAPLUS
DOCUMENT NUMBER: 90:204018
ORIGINAL REFERENCE NO.: 90:32461a,32464a
TITLE: Seven-membered N-heterocycles. XV. Ethyl 2-phenyl-7H-pyrimido[4,5-d]azepine 7-carboxylate
AUTHOR(S): Yamamoto, Hiroshi; Komazawa, Takao; Nakaue, Kazuyuki; Yokoo, Akira
CORPORATE SOURCE: Dep. Chem., Okayama Univ., Okayama, Japan
SOURCE: Heterocycles (1978), 11, 275-80
CODEN: HTCYAM; ISSN: 0385-5414
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 90:204018
GI



I

AB The title compound (I) was prepared from 6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine via the 6,7-dihydro-5h-derivative by stepwise dehydrogenation. Et 8,9-dihydro-7H-pyrimido[4,5-d]azepine-7-carboxylate was similarly prepared

IT 70269-68-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and dehydrobromination of)

RN 70269-68-0 CAPLUS

CN 7H-Pyrimido[4,5-d]azepine-7-carboxylic acid, 5-bromo-5,6-dihydro-2-phenyl-, ethyl ester (CA INDEX NAME)



IT 70269-63-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and dehydrogenation of)

RN 70269-63-5 CAPLUS

CN 7H-Pyrimido[4,5-d]azepine-7-carboxylic acid, 5,6-dihydro-2-phenyl-, ethyl ester (CA INDEX NAME)


N
Ph
EtO
C
N
N
O

L21 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1978:152465 CAPLUS
DOCUMENT NUMBER: 88:152465
ORIGINAL REFERENCE NO.: 88:24025a,24028a
TITLE: Studies on heterocyclic compounds. XLIII. Reaction of 1-phenyl-4-hydrazino-4,5-dihydro-6H-furo[2,3-d][1]benzazepine-5-carboxylic acid hydrazide with aromatic aldehydes
AUTHOR(S): Ito, Kazuo; Yakushijin, Kenichi; Yoshina, Shigetaka
CORPORATE SOURCE: Fac. Pharm., Meijo Univ., Nagoya, Japan
SOURCE: Heterocycles (1978), 9(2), 169-73
CODEN: HTCYAM; ISSN: 0385-5414
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB The title compound (I; R = H) reacted with R1CHO (R1 = 2-furyl, Ph, p-ClC6H4) in EtOH to give I (R2 = CHR1) and the monoarylidene derivative II.
IT 66206-57-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and condensation with aldehydes)
RN 66206-57-3 CAPLUS
CN 6H-Furo[2,3-d][1]benzazepine-5-carboxylic acid, 1-phenyl-, hydrazide (CA INDEX NAME)



IT 63874-16-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with hydrazine)

RN 63874-16-8 CAPLUS
CN 6H-Furo[2,3-d][1]benzazepine-5-carboxylic acid, 1-phenyl-, ethyl ester (CA INDEX NAME)



IT 66206-53-9P 66206-54-0P 66206-55-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 66206-53-9 CAPLUS
CN 6H-Furo[2,3-d][1]benzazepine-5-carboxylic acid, 1-phenyl-, 2-(2-furanylmethylene)hydrazide (CA INDEX NAME)



RN 66206-54-0 CAPLUS
CN 6H-Furo[2,3-d][1]benzazepine-5-carboxylic acid, 1-phenyl-, 2-(phenylmethylene)hydrazide (CA INDEX NAME)



RN 66206-55-1 CAPLUS
CN 6H-Furo[2,3-d][1]benzazepine-5-carboxylic acid, 1-phenyl-, 2-[(4-chlorophenyl)methylene]hydrazide (CA INDEX NAME)



L21 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1977:502204 CAPLUS
DOCUMENT NUMBER: 87:102204
ORIGINAL REFERENCE NO.: 87:16223a,16226a
TITLE: Studies on heterocyclic compounds. Part XXXI. Synthesis of ethyl 1-phenyl- and 2-methyl-6H-furo[2,3-d][1]benzazepine-5-carboxylates
AUTHOR(S): Yakushijin, Kenichi; Yoshina, Shigetaka; Tanaka, Akira
CORPORATE SOURCE: Fac. Pharm., Meijo Univ., Nagoya, Japan
SOURCE: Heterocycles (1977), 6(6), 721-5
CODEN: HTCYAM; ISSN: 0385-5414
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 87:102204
GI



I


II


III


IV

AB Thermolysis of I (R = Ph, R1 = H; R = H, R1 = Me) in ligroin gave II, which on thermolysis in boiling xylene gave III. Reduction of III with Zn in AcOH gave IV (R2 = CO2Et), which when treated with NaBH4 in EtOH gave IV (R2 = CH2OH), which was also obtained by direct reduction of III with NaBH4 in EtOH.

IT 63874-16-8P 63874-17-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

RN 63874-16-8 CAPLUS

CN 6H-Furo[2,3-d][1]benzazepine-5-carboxylic acid, 1-phenyl-, ethyl ester (CA INDEX NAME)



RN 63874-17-9 CAPLUS
CN 6H-Furo[2,3-d][1]benzazepine-5-carboxylic acid, 2-methyl-, ethyl ester (CA INDEX NAME)



L21 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1977:89889 CAPLUS
DOCUMENT NUMBER: 86:89889
ORIGINAL REFERENCE NO.: 86:14201a,14204a
TITLE: Azepino[4,5-b]quinoxalines
INVENTOR(S): Hurnaus, Rudolf; Griss, Gerhart; Grell, Wolfgang; Sauter, Robert; Reichl, Richard; Leitold, Matyas
PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
SOURCE: Ger. Offen., 46 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2519258	A1	19761111	DE 1975-2519258	19750430

PRIORITY APPLN. INFO.: DE 1975-2519258 19750430
GI



I

AB Tetrahydro-1H-azepino[4,5-b]quinoxalines (I; R = e.g., H, Me, Ph, PhCH2, Ac, Bz, CO2H, CH2CH2CO2H; R1 = R3 = H, OH, AcO, EtO2CO; R2n = e.g., H, 8-Cl, 7-NO2, 8-Me, 8-CO2H, 8,9-Me2, 8-MeO), useful as appetite depressants and bactericides (no data), are prepared by various known methods, mostly involving reaction between an o-phenylenediamine and an azepinedione. The azepinedione can be obtained by cyclization of an iminodipropionic acid derivative Thus, reaction of PhCH2N(CH2,cH2CO2Me) with Na and Me3SiCl in Me2C6H4 gives 1-benzyl-2,3,6,7-tetrahydro-4,5-bis(trimethylsiloxy)-1H-azepine which is oxidized with Br to the azepine-4,5-dione which then reacts with 1,2-(H2N)2C6H4 in AcOH to give after 4 hr at 100° 83% I.HCl (R = PhCH2, R1 = R2n = R3 = H).
IT 61793-97-3P 61793-98-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 61793-97-3 CAPLUS
CN 3H-Azepino[4,5-b]quinoxaline-3-carboxylic acid, 1,2-dihydro-, ethyl ester (CA INDEX NAME)



RN 61793-98-4 CAPLUS
CN 3H-Azepino[4,5-b]quinoxaline-3-carboxylic acid, 1-(acetyloxy)-1,2-dihydro-, ethyl ester (CA INDEX NAME)



L21 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1976:31038 CAPLUS
DOCUMENT NUMBER: 84:31038
ORIGINAL REFERENCE NO.: 84:5077a,5080a
TITLE: Quinoline derivatives
PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
SOURCE: Neth. Appl., 76 pp.
CODEN: NAXXAN
DOCUMENT TYPE: Patent
LANGUAGE: Dutch
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NL 7414720	A	19750521	NL 1974-14720	19741112
DE 2357253	A1	19750522	DE 1973-2357253	19731116
DE 2442097	A1	19760318	DE 1974-2442097	19740903
AU 7475357	A	19760520	AU 1974-75357	19741114

PRIORITY APPLN. INFO.: DE 1973-2357253 A 19731116
DE 1974-2442097 A 19740903

GI For diagram(s), see printed CA Issue.
AB Appetite-depressant azepinoquinolines (.apprx.300 compds.), including I(R = H, Et, CO2Et, Pr, CO2CMe3, CH2CHMeOH, CO2Me, R1 = Me, R = H, R1 = Pr) and II were prepared Thus hexahydro-4-azepinone-HCl was condensed with 2-H2NC6H4Ac to give I(R = H, R1 = Me) and II in 2:3 ratio. I(R = H, R1 = Me) and II gave 50% inhibition of feed uptake in rats at 0.2 and 1.1 mg/kg s.c. resp.
IT 57799-14-1P 57799-15-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 57799-14-1 CAPLUS
CN 3H-Azepino[4,5-b]quinoline-3-carboxylic acid, 1,2-dihydro-11-methyl-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 57799-15-2 CAPLUS
CN 1H-Azepino[4,5-b]quinoline, 2,3-dihydro-11-methyl- (CA INDEX NAME)


Me
HN
N

L19 ANSWER 17 OF 17 REGISTRY COPYRIGHT 2010 ACS on STN
RN 216-97-7 REGISTRY
ED Entered STN: 16 Nov 1984
CN 5H-Quinoxalino[2,3-d][1]benzazepine (CA INDEX NAME)
MF C16 H11 N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L19 ANSWER 16 OF 17 REGISTRY COPYRIGHT 2010 ACS on STN
RN 1139-56-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN Furo[2,3-d]pyrrolo[3,2,1-jk][1]benzazepine (8CI, 9CI) (CA INDEX NAME)
MF C14 H9 N O
CI RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L19 ANSWER 15 OF 17 REGISTRY COPYRIGHT 2010 ACS on STN
RN 42430-31-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4H-Pyrido[3,2,1-jk]quinoxalino[2,3-d][1]benzazepine (CA INDEX NAME)
MF C19 H13 N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L19 ANSWER 14 OF 17 REGISTRY COPYRIGHT 2010 ACS on STN
RN 80294-50-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN Oxazolo[5,4-d][1,4]thiazino[2,3,4-jk][1]benzazepine (9CI) (CA INDEX NAME)
MF C13 H8 N2 O S
CI RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L19 ANSWER 13 OF 17 REGISTRY COPYRIGHT 2010 ACS on STN
RN 80294-51-5 REGISTRY
ED Entered STN: 16 Nov 1984
CN [1,4]Thiazino[2,3,4-jk]thiazolo[5,4-d][1]benzazepine (9CI) (CA INDEX NAME)
MF C13 H8 N2 S2
CI RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L19 ANSWER 12 OF 17 REGISTRY COPYRIGHT 2010 ACS on STN
RN 112140-00-8 REGISTRY
ED Entered STN: 01 Jan 1988
CN 3,6-Methano-3H,4H-azeto[1',2':1,2]imidazo[4',5':4,5]azepino[3,2-b]pyrrolo[1,2-a]indole (9CI) (CA INDEX NAME)
MF C19 H14 N4
CI RPS
SR CA Index Guide or Ring Systems Handbook

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L19 ANSWER 11 OF 17 REGISTRY COPYRIGHT 2010 ACS on STN
RN 127036-88-8 REGISTRY
ED Entered STN: 11 May 1990
CN 8H-4,12b-Epoxypyrrolo[3',4':3,4]azepino[2,1-a]isoindole (9CI) (CA INDEX NAME)
MF C15 H10 N2 O
CI RPS
SR CA Index Guide or Ring Systems Handbook



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L19 ANSWER 10 OF 17 REGISTRY COPYRIGHT 2010 ACS on STN
RN 147184-23-4 REGISTRY
ED Entered STN: 23 Apr 1993
CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepine,
10-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinylidene]- (CA INDEX NAME)
MF C24 H25 N3 O S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L19 ANSWER 9 OF 17 REGISTRY COPYRIGHT 2010 ACS on STN
RN 147210-28-4 REGISTRY
ED Entered STN: 27 Apr 1993
CN 5H-Thiazolo[3,2-a]pyrimidin-5-one,
6-[2-[4-(10H-imidazo[1,2-a]thieno[3,2-d]azepin-10-ylidene)-1-
piperidinyl]ethyl]-7-methyl- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepine, 5H-thiazolo[3,2-a]pyrimidin-5-one
deriv.
MF C24 H23 N5 O S2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L19 ANSWER 9 OF 17 REGISTRY COPYRIGHT 2010 ACS on STN
RN 147210-28-4 REGISTRY
ED Entered STN: 27 Apr 1993
CN 5H-Thiazolo[3,2-a]pyrimidin-5-one,
6-[2-[4-(10H-imidazo[1,2-a]thieno[3,2-d]azepin-10-ylidene)-1-
piperidinyl]ethyl]-7-methyl- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 10H-Imidazo[1,2-a]thieno[3,2-d]azepine, 5H-thiazolo[3,2-a]pyrimidin-5-one
deriv.
MF C24 H23 N5 O S2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L19 ANSWER 5 OF 17 REGISTRY COPYRIGHT 2010 ACS on STN
RN 719305-66-5 REGISTRY
ED Entered STN: 30 Jul 2004
CN 4H-Imidazo[1,2-a]oxazolo[4,5-d]azepine (9CI) (CA INDEX NAME)
MF C9 H7 N3 O
CI RPS
SR CA Index Guide or Ring Systems Handbook



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L19 ANSWER 6 OF 17 REGISTRY COPYRIGHT 2010 ACS on STN
RN 700373-43-9 REGISTRY
ED Entered STN: 28 Jun 2004
CN 2H,3H-Oxeto[3,2-d]pyrrolo[1,2-a]azepine (9CI) (CA INDEX NAME)
MF C10 H9 N O
CI RPS
SR CA Index Guide or Ring Systems Handbook
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L19 ANSWER 7 OF 17 REGISTRY COPYRIGHT 2010 ACS on STN
RN 279253-81-5 REGISTRY
ED Entered STN: 21 Jul 2000
CN Spiro[cyclohexane-1,10'-[10H]imidazo[1,2-a]thieno[3,2-d]azepine] (9CI)
(CA INDEX NAME)
MF C15 H16 N2 S
CI COM, RPS
SR CA

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L19 ANSWER 8 OF 17 REGISTRY COPYRIGHT 2010 ACS on STN
RN 188965-71-1 REGISTRY
ED Entered STN: 13 May 1997
CN 4H-Pyrrolo[1,2-a]thieno[3,2-d]azepine (9CI) (CA INDEX NAME)
MF C11 H9 N S
CI RPS
SR CA Index Guide or Ring Systems Handbook



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT